Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717111 | 0.89 | L3MBTL1 (0.59) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL2713694 | 0.88 | L3MBTL1 (0.57) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL2715385 | 0.87 | L3MBTL1 (0.57) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL458559 | 0.85 | L3MBTL1 (1.00) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL29488316 | 0.85 | L3MBTL1 (1.00) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL2713868 | 0.85 | L3MBTL1 (0.55) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL13875896 | 0.84 | L3MBTL1 (0.70) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL20474664 | 0.84 | L3MBTL1 (0.70) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL2715509 | 0.84 | L3MBTL1 (0.70) | L3MBTL1POLBMAPK1MAPTEPHX2 | |
| SCHEMBL2713919 | 0.84 | EPHX2 (0.60) | L3MBTL1MAPTEPHX2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020215094-A1 | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2018-09-06 | — | — | US | disclosed |
| EP-2729447-B1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H LUNDBECK AS (DK) | 2018-05-30 | — | — | EP | disclosed |
| US-9889122-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2018-02-13 | — | — | US | disclosed |
| US-9889122-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2018-02-13 | — | — | US | disclosed |
| US-9889122-B2 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2018-02-13 | — | — | US | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | H. LUNDBECK A/S (DK) | 2017-03-23 | — | — | US | disclosed |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | H. LUNDBECK A/S (DK) | 2017-03-23 | — | — | US | disclosed |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | H. LUNDBECK A/S (DK) | 2017-03-23 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1802632-B1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-1802632-A1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | Dow AgroSciences LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006047397-A1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089370-A1 | Thieno-pyrimidine compounds having fungicidal activity | BREWSTER WILLIAM K | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250277-A1 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | CHRNG, CHRNA7, CHRNA2 | L3MBTL1 3420/4885POLB 3799/4885MAPK1 2893/4885 |
| US-20060089370-A1 | Thieno-pyrimidine compounds having fungicidal activity | TYMP, DPM1, TYMS | L3MBTL1 1757/4885POLB 1504/4885MAPK1 3595/4885 |
| US-20130012530-A1 | New Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | L3MBTL1 3488/4885POLB 3862/4885MAPK1 2633/4885 |
| US-20170079967-A1 | New Positive Allosteric Modulators or Nicotinic Acetylcholine Receptor | CHRNG, CHRNA7, CHRNA1 | L3MBTL1 3451/4885POLB 3833/4885MAPK1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.